Abstract YO33
Case summary
Background
Hyponatremia is known to be a modifiable prognostic factor in advanced cancer. It is also known to be a medical emergency. Correction of hyponatremia in the absence of urinary analysis and radiological investigations is a challenge. This case report discusses the feasibility and challenges involved in correction of hyponatremia in the Palliative medicine ward.
Case details
62 year old male patient with a smoking index of 2000, a known case of Adenocarcinoma of the lung with adrenal, liver and brain metastasis presented with backache, weakness and obstructive urinary symptoms. A biopsy done from the site of a pelvic fracture that he had obtained in the recent past was suggestive of a poorly differentiated tumor. A biopsy from the right lung mass was reported as adenocarcinoma. He was bieng evaluated for potentially reversible causes of deterioration in general medical condition during which routine biochemical and haematological investigations were sent. The successive serum sodium levels were found to be 100, less than 100, 82.8, 111 and 114.8 meq /l during the course of the next 12 hours. Fluid restriction was initiated after a presumptive diagnosis of Syndrome of Inappropriate ADH secretion had been considered. The 24 hour urine output was 2250 ml.
Discussion
The following questions with regards to the management of hyponatremia in advanced cancer merit further discussion – Is the palliative medicine ward a feasible setting for the management of an oncological emergency, can the diagnosis of SIADH be made presumptively in the absence of urine analysis, does the syndrome of cerebral salt wasting exist as a separate entity and are vaptans useful in the management of hyponatremia.
Laboratory parameters | 0 hours | +6 hours | +12 hours |
Serum Haemoglobin | 9.7 | 10.6 | |
Total Leucocyte count | 18800 | 21680 | |
Total Platelet count | 64000 | 85000 | |
ESR | 70 | ||
pH | 7.46 | 7.42 | 7.46 |
pCO2 | 26 | 30 | 25 |
pO2 | 41 | 49 | 68 |
Sodium | 100 | <100 | 82.8 |
Potassium | 4.9 | 4.4 | 5.7 |
Calcium | 0.40 | 0.59 | 0.92 |
Glucose | 101 | 203 | 195 |
Lactate | 1.4 | 1.6 | |
Bicarbonate | 18.5 | 26.4 | |
Total Co2 | 19.3 | 20.4 | |
Base equivalents | 5.3 | 4.1 | |
SpO2 | 80 | 82 |
Clinical trial identification
Editorial acknowledgement
Resources from the same session
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract